Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Merck, PAREXEL Form Strategic Biosimilar Alliance | Contract Pharma

What are you searching for?

Sign in
Breaking News

Merck, PAREXEL Form Strategic Biosimilar Alliance

Merck and PAREXEL International Corp. have entered into an alliance under which PAREXEL will provide access to global clinical development services for designated biosimilar candidates to Merck BioVentures, a division of Merck.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Merck and PAREXEL International Corp. have entered into an alliance under which PAREXEL will provide access to global clinical development services for designated biosimilar candidates to Merck BioVentures, a division of Merck.

PAREXEL will provide access to regulatory strategy and clinical development planning capabilities for the development of various classes of biosimilars across multiple therapeutic areas, including exclusivity for certain candidates. The agreement also provides for the establishment of a dedicated Merck BioVentures unit within the PAREXEL organization.

“PAREXEL has extensive, industry-leading experience with biosimilar development, and we truly understand the scientific complexities, and regulatory pathways involved,” said Josef von Rickenbach, chairman and chief executive officer of PAREXEL. “We are committed to working with Merck BioVentures to assist in advancing its biosimilar portfolio in this rapidly developing market segment for the benefit of patients worldwide.”

“Through this agreement, Merck BioVentures has secured broad strategic access to PAREXEL’s proven biosimilar clinical development experience,” said Michael Kamarck, president of Merck BioVentures. “This agreement positions Merck BioVentures for success with an industry leading partner that has the expertise and resources to conduct clinical development of our diverse portfolio of candidates to allow timely delivery of products to the marketplace.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics